EVOK Stock UPDATES Evoke Pharma Inc (EVOK) 5.07 10/22/2014 0

New Post Public Reply Private Reply Replies (0) Message Board

Oct 22, 2014 at 3:42 AM

Evoke Pharma Inc (EVOK) 5.07 $EVOK

Nasdaq stocks posting largest percentage decreases
AP - Fri Sep 19, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
EVOK: 5.07 (unch), ALCS: 0.30 (+0.01), UNXL: 4.97 (-0.03), RXDX: 6.97 (+0.01), FULL: 6.04 (+0.03), RLYP: 18.77 (-0.33), BBSI: 43.42 (+1.13), NVSL: 7.77 (-0.02), RPRX: 6.02 (-0.21), HGSH: 4.21 (+0.24), LPCN: 4.88 (+0.08), NYNY: 6.64 (-0.01)

Evoke Pharma completes enrollment of ECG Study of EVK-001 for diabetic gastroparesis ahead of schedule
M2 - Wed Sep 10, 6:22AM CDT
Pharmaceutical company Evoke Pharma (NasdaqCM:EVOK) disclosed on Tuesday that it has completed the enrollment in its thorough ECG (electrocardiogram) (QT) study of its lead product candidate EVK-001.
EVOK: 5.07 (unch)

Evoke Pharma Announces the Completion of Enrollment in Its Thorough ECG Study for EVK-001
GlobeNewswire - Tue Sep 09, 7:30AM CDT
Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it has completed enrollment in its thorough ECG (QT) study of EVK-001, the Company's lead product candidate. EVK-001 is currently in a Phase 3 clinical trial for the relief of symptoms associated with acute and recurrent gastroparesis in women with diabetes mellitus.
EVOK: 5.07 (unch)

Evoke Pharma to Present at the Aegis Capital Corp. 2014 Healthcare & Technology Conference
GlobeNewswire - Thu Sep 04, 7:35AM CDT
Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that Dave Gonyer, CEO, will present a corporate overview at the Aegis Capital Corp. 2014 Healthcare & Technology Conference, being held September 10-13, 2014 at The Encore at The Wynn in Las Vegas, Nevada. The Company is scheduled to present on Thursday, September 11, 2014 at 2:00pm PT. A copy of the corporate overview will be posted to the company's website following the presentation.
EVOK: 5.07 (unch)

Evoke Pharma Reports Second Quarter 2014 Results
GlobeNewswire - Wed Aug 13, 3:01PM CDT
Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the second quarter ended June 30, 2014.
EVOK: 5.07 (unch)

Evoke Pharma Announces Initiation of a Thorough ECG (QT) Study for EVK-001
GlobeNewswire - Tue Aug 12, 4:42PM CDT
Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the initiation of its thorough ECG (QT) study of the Company's lead product candidate, EVK-001, which is currently in a Phase 3 clinical trial for the relief of symptoms associated with acute and recurrent gastroparesis in women with diabetes mellitus.
EVOK: 5.07 (unch)

Nasdaq stocks posting largest volume decreases
AP - Tue Aug 05, 5:06PM CDT
NEW YORK (AP) — A look at the 10 biggest volume decliners on Nasdaq at the close of trading:
MCBK: 19.10 (+0.10), EVOK: 5.07 (unch), SBBX: 9.95 (+0.11), THRD: 41.16 (+0.50), NECB: 6.85 (-0.12), CBIN: 26.50 (unch), AMIC: 10.04 (-0.81), BRID: 8.50 (+0.01), SLTC: 5.72 (-0.23)

Evoke Pharma Schedules Webcast and Conference Call for Second Quarter 2014 Financial Results
GlobeNewswire - Wed Jul 30, 7:40AM CDT
Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will issue its financial results for the second quarter of 2014 on Wednesday, August 13, 2014, after the close of the market.
EVOK: 5.07 (unch)

Evoke Pharma Reports Fourth Quarter and Year End 2013 Results
GlobeNewswire - Tue Mar 25, 3:30PM CDT
Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the fourth quarter and year ended December 31, 2013.
EVOK: 5.07 (unch)

Evoke Pharma Schedules Webcast and Conference Call for Fourth Quarter 2013 Financial Results
GlobeNewswire - Mon Mar 10, 9:02AM CDT
Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will issue its financial results for the Fourth Quarter of 2013 on Tuesday, March 25, 2014, after the close of the market.
EVOK: 5.07 (unch)

Evoke Pharma to Present at 26th Annual ROTH Conference
GlobeNewswire - Tue Mar 04, 7:30AM CST
Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that its President and Chief Executive Officer, Dave Gonyer, R.Ph., will be presenting at the 26 Annual ROTH Conference, being held March 10-12, 2014 at the Ritz-Carlton in Dana Point, California.
EVOK: 5.07 (unch)

Diabetic Gastroparesis - Pipeline Review, H1 2014 Research Report
M2 - Mon Feb 24, 3:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/7ctztm/diabetic) has announced the addition of the "Diabetic Gastroparesis - Pipeline Review, H1 2014" report to their offering. 'Diabetic Gastroparesis - Pipeline Review, H1 2014', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Diabetic Gastroparesis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Diabetic Gastroparesis. Scope - A snapshot of the global therapeutic scenario for Diabetic Gastroparesis. - A review of the Diabetic Gastroparesis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Diabetic Gastroparesis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Diabetic Gastroparesis Overview Therapeutics Development Late Stage Products Clinical Stage Products Early Stage Products Unknown Stage Products Assessment by Monotherapy Products Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Assessment by Therapeutic Class Drug Profiles metoclopramide hydrochloride - Drug Profile RM-131 - Drug Profile velusetrag - Drug Profile Non-Antibiotic Macrolide Program for Gastric Disorders - Drug Profile TC-6499 - Drug Profile Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned Theravance, Inc. Evoke Pharma, Inc. Targacept, Inc. Cempra, Inc. Rhythm Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/7ctztm/diabetic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
EVOK: 5.07 (unch), TRGT: 2.34 (-0.01), THRX: 18.64 (+0.69), CEMP: 12.19 (-0.03)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

KINGRVER Boosts RV Comfort with New Water Heater Lineup

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Servier's Data on Tovorafenib Shows Promise in pLGG

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

Portillo's Faces Class Action: Investor Losses at Stake

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

EZaccessMD Data Breach: Class Action Lawsuit Looms

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

JOYEE N01 Debuts Globally with First 2,000 Deliveries

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

CVS Study: GLP-1 Drugs Effective But Costly

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Layne's Chicken Fingers Expands with Brownsville Opening

Fried Delights Rise in Brownsville Never thought I'd see the day when chicken fingers felt like the main character in an epic expansion saga, but here we are. Ricki Oberoi, a veteran in the fast-food game, is pushing onward with Layne's Chicken Fingers in Brownsville, Texas. I tell you, some folks are as keen on expanding their palates as they are their portfolios....

D-Wave Quantum Hit with Securities Fraud Lawsuit

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...